Is It Game Over for Celldex? [The Motley Fool]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: The Motley Fool
Celldex’s lead drug is a flop, but it still has other irons in the fire. Celldex ( NASDAQ:CLDX ) has unveiled thoroughly disappointing results for its lead drug, glembatumumab vedotin (glemba), that casts doubt on its future. Can the company bounce back from this failure? In this clip from The Motley Fool's Industry Focus: Healthcare , Motley Fool contributor Todd Campbell joins host Kristine Harjes to explain what's next for the company following its decision to halt glemba's development. A full transcript follows the video. This video was recorded on April 18, 2018. Kristine Harjes: Todd, we heard all about Alkermes ' latest news. What else has been going on? Todd Campbell: I think the investors that have followed the Fool for years and years might recognize this second company that I thought we should talk about today, Kristine, and that's Celldex Therapeutics. Harjes: Yeah. Campbell: Do you remember that, Kristine, Celldex?
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.MarketBeat
- Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceGlobeNewswire
- Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care ConferenceGlobeNewswire
- Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
CLDX
Earnings
- 2/26/24 - Miss
CLDX
Sec Filings
- 3/1/24 - Form 8-K
- 3/1/24 - Form 424B5
- 2/28/24 - Form 424B5
- CLDX's page on the SEC website